ssociated with obtaining regulatory
approvals, unforeseen technical difficulties, dependencies on certain
customers or products, market acceptance and competition, ability to
receive grant and contract revenue and procurement funding, ability to
identify any additional strategic acquisitions or other opportunities to
accelerate growth, cash at the end of the year, as well as other risks
described in the Company's filings with the Securities and Exchange
Commission, in conference calls and in other communications.
PHARMATHENE, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
December 31,
2007 2006
Current assets:
Cash and cash equivalents $40,582,643 $5,112,212
Short-term investments 12,153,945 -
Accounts receivable 5,245,763 1,455,538
Prepaid expenses 476,511 877,621
Other current assets 15,783 104,772
Total current assets 58,474,645 7,550,143
Property and equipment, net 6,571,024 5,230,212
Patents, net 1,312,991 1,246,236
Other long term assets 183,588 153,336
Deferred costs 68,884 587,577
Total assets $66,611,132 $14,767,504
LIABILITIES, CONVERTIBLE REDEEMABLE
PREFERRED STOCK, AND STOCKHOLDERS' DEFICIT
Current Liabilities:
Accounts payable $1,393,664 $839,120
Accrued expenses and other liabilities 3,602,886 1,587,017
Notes pay
'/>"/>
SOURCE PharmAthene, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1.
Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.2.
Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court3.
PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services4.
Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA5.
PharmAthene to Present at the BIO CEO & Investor Conference 20086.
PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations7.
PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 20088.
PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference9.
PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia10.
PharmAthene to Delay Release of Full Year 2007 Financial Results11.
PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008